BridgeBio Pharma LLC - Aug 11, 2025 Form 3 Insider Report for BridgeBio Oncology Therapeutics, Inc. (BBOT)

Role
10%+ Owner
Signature
/s/ Neil Kumar, Chief Executive Officer of BridgeBio Pharma LLC
Stock symbol
BBOT
Transactions as of
Aug 11, 2025
Transactions value $
$0
Form type
3
Date filed
8/18/2025, 05:16 PM
Next filing
Oct 16, 2025
SEC
View on sec.gov

Reporting Owners (2)

Name Relationship Address Signature Signature date CIK
BridgeBio Pharma LLC 10%+ Owner C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DRIVE, SUITE 250, PALO ALTO /s/ Neil Kumar, Chief Executive Officer of BridgeBio Pharma LLC 2025-08-18 0002076615
BridgeBio Pharma, Inc. 10%+ Owner 3160 PORTER DR., SUITE 250, PALO ALTO /s/ Neil Kumar, Chief Executive Officer of BridgeBio Pharma, Inc. 2025-08-18 0001743881

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BBOT Common Stock 13.8M Aug 11, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BBOT Stock Option (Right to Buy) Aug 11, 2025 Common Stock 63.9K $3.83 Direct F3
holding BBOT Stock Option (Right to Buy) Aug 11, 2025 Common Stock 9.49K $1.02 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares are held by BridgeBio Pharma LLC ("BBIO LLC"). Voting and investment power over the shares held by BBIO LLC is exercised by its parent entity, BridgeBio Pharma, Inc. ("BBIO"). The board of directors of BBIO consists of Neil Kumar, Ph.D., Eric Aguiar, M.D., Jennifer E. Cook, Douglas A. Dachille, Ronald J. Daniels, Andrea J. Ellis, Fred Hassan, Charles Homcy, M.D., Andrew W. Lo, Ph.D., Frank P. McCormick, Ph.D., F.R.S., D.Sc., James C. Momtazee, Ali J. Satvat, Randal W. Scott, Ph.D., and Hannah A. Valantine, M.D. (each a BBIO director, and collective, the BBIO Directors"). None of the members of the board of directors of BBIO or BBIO LLC has individual voting or investment power with respect to such shares. Each of BBIO and the BBIO Directors disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its, his, or her pecuniary interest therein, if any.
F2 (Continued from Footnote 1) This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F3 The shares subject to such option are fully vested.